ArticleCureus2024
Dilated Cardiomyopathy, De Novo Heart Failure, and Cardiogenic Shock With End-Organ Failure in a Patient With No Cardiac History Following a Trial of Amitriptyline.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 69-year-old female with no cardiac history presented with dilated cardiomyopathy and de novo congestive heart failure, with an ejection fraction of less than 20%. This patient had struggled over the prior six weeks with exacerbation of chronic obstructive pulmonary disease complicated by pneumonia and as such had taken several trials of antibiotics. Four days prior to her presentation, she was prescribed amitriptyline by her primary care physician to help with sleep. Two days after the presentation, she developed cardiogenic shock secondary to acutely decompensated heart failure. End-organ dysfunction presented as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of greater than 1000 U/L and a glomerular filtration rate (GFR) as low as 23 mL/min. Cardiac catheterization showed non-obstructive coronary artery disease, and cardiac MRI showed an ejection fraction of 14%. She was discharged 14 days after her initial presentation with a diagnosis of NYHA Class 3 Stage C acute systolic heart failure with dilated cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.